APPLICATION OF STEM CELLS IN TREATMENT OF ORAL LICHEN PLANUS

Background: Oral lichen planus (OLP) is a chronic inflammatory mucocutaneous disorder of autoimmune origin, often presenting as painful erosive or atrophic lesions in the oral cavity. Conventional therapies such as corticosteroids and immunosuppressants offer temporary relief but are associated with side effects and recurrence. Recent advancements in regenerative medicine highlight mesenchymal stem cells (MSCs), particularly gingiva-derived MSCs (GMSCs), for their immunomodulatory and regenerative potential. Objective: This study aimed to evaluate the safety and clinical efficacy of autologous gingiva-derived mesenchymal stem cells in the management of erosive OLP through a randomized, double-blind, placebo-controlled clinical trial. Methods: A total of 48 patients aged 30–65 years with clinically and histopathologically confirmed erosive OLP were randomized into two groups (n=24 each). The experimental group received three biweekly submucosal injections of GMSCs (1×10⁶ cells/mL), while the control group received placebo saline injections. Pain was assessed using the Visual Analog Scale (VAS), lesion size measured via digital calipers, and lesion severity evaluated using the Thongprasom score. Quality of life was assessed with the OHIP-14 questionnaire, and salivary levels of IL-6 and TNF-α were analyzed using ELISA at baseline, 2, 4, and 12 weeks post-treatment. Safety and adverse events were also monitored. Results: The MSC group demonstrated significant reductions in pain (VAS: from 6.9 to 1.0), lesion size (from 86.5 mm² to 20.7 mm²), and Thongprasom score (from 4.3 to 0.8) by week 12 (p<0.001). Salivary cytokines IL-6 and TNF-α significantly decreased, indicating reduced inflammation. Adverse events were mild and comparable between groups. Conclusion: GMSC therapy is a safe and effective treatment for erosive OLP, offering substantial clinical improvement and anti-inflammatory benefits. These findings support the potential of stem cell-based therapies as a regenerative alternative for chronic oral autoimmune conditions.

Authors

Institutions

Publication Details

Journal
Journal of medical & health sciences review.
Published
2025-03-30
DOI
https://doi.org/10.62019/5ejb0e91
Primary Topic
Oral Health Pathology and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

APPLICATION OF STEM CELLS IN TREATMENT OF ORAL LICHEN PLANUS

Ali Akram, D Amanat, Muhammad Arif, Dr Azaz Ali Shah et al.
Journal of medical & health sciences review.
Oral Health Pathology and Treatment
article

APPLICATION OF STEM CELLS IN TREATMENT OF ORAL LICHEN PLANUS

Ali Akram, D Amanat, Muhammad Arif, Dr Azaz Ali Shah, Momminah Qamar, Dr Ashar Hussain
article en

Abstract

Background: Oral lichen planus (OLP) is a chronic inflammatory mucocutaneous disorder of autoimmune origin, often presenting as painful erosive or atrophic lesions in the oral cavity. Conventional therapies such as corticosteroids and immunosuppressants offer temporary relief but are associated with side effects and recurrence. Recent advancements in regenerative medicine highlight mesenchymal stem cells (MSCs), particularly gingiva-derived MSCs (GMSCs), for their immunomodulatory and regenerative potential. Objective: This study aimed to evaluate the safety and clinical efficacy of autologous gingiva-derived mesenchymal stem cells in the management of erosive OLP through a randomized, double-blind, placebo-controlled clinical trial. Methods: A total of 48 patients aged 30–65 years with clinically and histopathologically confirmed erosive OLP were randomized into two groups (n=24 each). The experimental group received three biweekly submucosal injections of GMSCs (1×10⁶ cells/mL), while the control group received placebo saline injections. Pain was assessed using the Visual Analog Scale (VAS), lesion size measured via digital calipers, and lesion severity evaluated using the Thongprasom score. Quality of life was assessed with the OHIP-14 questionnaire, and salivary levels of IL-6 and TNF-α were analyzed using ELISA at baseline, 2, 4, and 12 weeks post-treatment. Safety and adverse events were also monitored. Results: The MSC group demonstrated significant reductions in pain (VAS: from 6.9 to 1.0), lesion size (from 86.5 mm² to 20.7 mm²), and Thongprasom score (from 4.3 to 0.8) by week 12 (p<0.001). Salivary cytokines IL-6 and TNF-α significantly decreased, indicating reduced inflammation. Adverse events were mild and comparable between groups. Conclusion: GMSC therapy is a safe and effective treatment for erosive OLP, offering substantial clinical improvement and anti-inflammatory benefits. These findings support the potential of stem cell-based therapies as a regenerative alternative for chronic oral autoimmune conditions.

Journal of medical & health sciences review.Vol. 2(1)
Karachi Medical and Dental College (PK), Diné College (US), Isra University (PK), Benazir Bhutto Hospital (PK), Collège Montmorency (CA), City University of Science and Information Technology (PK)
Openalex Percentile: Top 93%
Oral Health Pathology and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.